ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2025
Mucosamin Spray for the Prevention of Oral Mucositis in Cancer Patients Receiving Chemotherapy: A Retrospective Cohort Study.
Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionIt has been suggested that hyaluronic acid can prevent oral mucositis in patients receiving cancer treatment. We aimed to compare the efficacy of a commercial preparation of sodium hyaluronate spray supplemented with a pool of amino acids (Mucosamin) to standard oral care (SOC) in the prevention of chemotherapy-induced oral mucositis.
methodsIn this retrospective cohort study, consecutive cancer patients who had received chemotherapy without prior or concomitant radiotherapy at a tertiary care University Hospital in Naples, Italy, were eligible for inclusion. The exposure of interest was the use of Mucosamin spray prior to commencing the prescribed cycle of chemotherapy. The primary endpoint of the study was the onset of oral mucositis in both groups during and after their chemotherapy regimens. The secondary endpoint was to determine the severity of pain for patients who developed oral mucositis in either group.
resultsA reduction was observed in the incidence of mucositis in patients who had used Mucosamin prophylactically (4%, 2/57) compared to SOC (33%, 16/49), with an effect size ϕ of 0.39. Patients in the Mucosamin group experienced a significant risk reduction (RR = 0.11; 95% CI 0.03-0.44). The use of Mucosamin resulted in an absolute risk reduction of 29.14%, and the number needed to treat to prevent one additional case of mucositis was 3.43. DISCUSSION: Our results show that cancer patients receiving Mucosamin spray prior to the commencement of chemotherapy are at a reduced risk of developing oral mucositis compared to those receiving care as usual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.